refametinib   Click here for help

GtoPdb Ligand ID: 7942

Synonyms: BAY-869766 | RDEA119
PDB Ligand
Compound class: Synthetic organic
Comment: Refametinib (BAY-869766) is a potent and selective, allosteric inhibitor of MEK1/2 with potential antineoplastic activity [1]. This compound is available via AstraZeneca's openinnovation toolbox resource, which indicates that refametinib is associated with a risk of fetal toxicity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 9
Topological polar surface area 116.27
Molecular weight 572.01
XLogP 3.2
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC(CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O
Isomeric SMILES OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O
InChI InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
InChI Key RDSACQWTXKSHJT-NSHDSACASA-N
No information available.
Summary of Clinical Use Click here for help
Phase I clinical trial results have been published [2]. Phase II clinical trials are underway for advanced or metastatic cancer, including RAS mutant hepatocellular carcinoma (HCC), assessing refametinib alone or in combination with either sorafenib or regorafenib, which are both approved multikinase inhibitors. View these refametinib clinical trial records at ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The MEK enzyme is highly selective for its target ERK. Inhibition of MEK therefore selectively inhibits activation of the ERK signalling pathway which drives cell proliferation.